4
15
10
↑4
↓15
—10
Evidence suggests Melatonin maydecreaseFatigue.
24 studies (29 claims)
Emerging evidence
Typical effective dose 5 (3–18) mgacross 13 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| sustained release melatonin 10mg u.i.d. | No effect - not associated with a significant reduction | perceived fatigue | Human | melatonin-treated subjects | 10mg sustained-release melatonin once daily (u.i.d.). | Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. |
| sustained release melatonin 10mg u.i.d. | No effect - not associated with a significant reduction | perceived fatigue | Human | melatonin-treated subjects | 10mg sustained-release melatonin once daily (u.i.d.). | Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. |
| switch from melatonin to agomelatine | Decreases - was associated with a reduction | fatigue levels | Human | melatonin-treated subjects | 10mg sustained-release melatonin once daily (u.i.d.). | Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. |
| switch from melatonin to agomelatine | Decreases - was associated with a reduction | fatigue levels | Human | melatonin-treated subjects | 10mg sustained-release melatonin once daily (u.i.d.). | Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. |
| melatonin 20 mg | No effect - did not demonstrate statistical significance | FACIT-Fatigue scale | Human | patients with breast cancer undergoing RT | 20 mg orally, starting the night before radiotherapy initiation until 2 weeks post-radiotherapy. | Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial.cited 6× |
| melatonin 20 mg | No effect - did not prevent or significantly improve | fatigue and other symptoms | Human | patients with early stage breast cancer undergoing RT | 20 mg orally, starting the night before radiotherapy initiation until 2 weeks post-radiotherapy. | Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial.cited 6× |
| melatonin | No effect - preliminary data suggest is useful | chronic fatigue syndrome | Human | — | Not specified | Clinical uses of melatonin: evaluation of human trials.cited 219× |
| melatonin | Increases - trend for beneficial effect | cognitive subscore of the Modified Fatigue Impact Scale | Human | relapsing-remitting MS (RRMS) patients receiving once weekly interferon beta | 3 mg/day | Impact of Melatonin on Motor, Cognitive and Neuroimaging Indices in Patients with Multiple Sclerosis.cited 22× |
| melatonin | No effect - no significant difference in the occurrence | common adverse drug reactions, such as drowsiness and fatigue | Human | adults with migraine | — | Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.cited 4× |
| melatonin | Decreases - may protect against | exercise-induced fatigue and impairments | Human | — | Not specified | Melatonin plus exercise-based neurorehabilitative therapy for spinal cord injury.cited 57× |
| melatonin | Decreases - found to reduce fatigue | fatigue | Human | individuals with traumatic brain injury | Not specified | Fatigue After Traumatic Brain Injury: A Systematic Review.cited 20× |
| melatonin (MLT) | No effect - had no significant effect on | fatigue | Human | patients with cancer | — | Effect of melatonin on quality of life and symptoms in patients with cancer: a systematic review and meta-analysis of randomised controlled trials.cited 10× |
| melatonin | Decreases - reduced | fatigue | Human | — | Not specified | Melatonin as a Novel Drug to Improve Cardiac Function and Quality of Life in Heart Failure Patients: A Systematic Review and Meta-Analysis. |
| melatonin (18 mg/day) | Decreases - decreased | fatigue associated with the malignant condition and its treatments | Human | women with breast cancer | 18 mg/day | A Randomized, Controlled, Parallel-Group, Trial on the Long-term Effects of Melatonin on Fatigue Associated With Breast Cancer and Its Adjuvant Treatments.cited 13× |
| melatonin (18 mg/day) | Decreases - decreased | levels of fatigue | Human | breast cancer patients | 18 mg/day | A Randomized, Controlled, Parallel-Group, Trial on the Long-term Effects of Melatonin on Fatigue Associated With Breast Cancer and Its Adjuvant Treatments.cited 13× |
| melatonin | Increases - significant improvement | fatigue severity | Human | breast cancer patients | 5 mg at bedtime | The effect of melatonin on sleep and quality of life in patients with advanced breast cancer.cited 74× |
| melatonin | No effect - No significant differences between the placebo and melatonin periods were found for | physical fatigue | Human | patients with advanced cancer | 20 mg orally each night. | Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial.cited 32× |
| melatonin at a dose of 20 mg | No effect - was not found to improve | fatigue | Human | patients with advanced cancer | 20 mg orally each night. | Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial.cited 32× |
| melatonin | Decreases - reductions in | self-reported fatigue | Human | participants with TBI-induced sleep disturbance | — | The Utility of Melatonin for the Treatment of Sleep Disturbance After Traumatic Brain Injury: A Scoping Review.cited 8× |
| melatonin as adjunct treatment concurrent with chemotherapy or radiotherapy | Decreases - dramatically decreased | radiochemotherapy-related side effects including fatigue | Human | solid tumor cancer patients | 20 mg orally, once a day. | The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials.cited 105× |
| standard of care plus melatonin at a dose of 3 mg three times daily for 14 d | Decreases - significantly improved | clinical symptoms such as cough, dyspnea, and fatigue | Human | hospitalized patients with confirmed mild to moderate COVID-19 | 3 mg three times daily | Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial.cited 58× |
| melatonin supplementation | Increases - suggested improvements in | fatigue | Human | patients with MS | Not specified | Clinical efficacy and safety of melatonin supplementation in multiple sclerosis: a systematic review.cited 11× |
| melatonin supplementation | Decreases - decreased | fatigue on the Fatigue Severity Scale | Human | patients with traumatic brain injury (TBI) | 2 mg prolonged-release melatonin (Circadin®) nightly, 2 hours before bedtime. | Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial.cited 88× |
| melatonin supplementation (3 mg/night for 12 weeks) | Decreases - decreased | Fatigue Severity Scale (FSS) scores | Human | persons with multiple sclerosis (PwMS) | 3 mg/night | 12-week melatonin supplementation improved dynamic postural stability and walking performance in persons living with multiple sclerosis: A randomized controlled trial.cited 3× |
| melatonin supplementation | No effect - did not significantly change | modified fatigue impact scale (MFIS) scores | Human | patients with relapsing forms of multiple sclerosis (RMS) | 3 mg or 5 mg daily. | Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis. |
| melatonin supplementation | Decreases - could be ameliorated | sleep disturbance and fatigue | Human | children with persistent post-concussion symptoms (PPCS) | 3 mg or 10 mg of melatonin. | Neural Correlates of Sleep Recovery following Melatonin Treatment for Pediatric Concussion: A Randomized Controlled Trial.cited 17× |
| oral melatonin (as Circadin) 2 mg at night | No effect - investigate the effects | fatigue | Human | adults with severe non-malignant pain of at least 3 months' duration | 2 mg daily (as modified-release Circadin) | Phase II double-blind randomised controlled trial of exogenous administration of melatonin in chronic pain (DREAM-CP): a study protocol.cited 3× |
| Melatonin plus standard treatment | No effect - We are also very uncertain about potential adverse effects | fatigue | Human | adult participants with cancer | Not specified in the abstract. | Melatonin in cancer treatment.cited 1× |
| Melatonin plus standard treatment | Decreases - likely reduces the incidence of | fatigue | Human | adult participants with cancer | Not specified in the abstract. | Melatonin in cancer treatment.cited 1× |
| melatonin coadministration | Decreases - decreased | levels of fatigue associated with the malignant condition and its treatments | Human | women with breast cancer | Not specified | A Randomized, Controlled, Parallel-Group, Trial on the Effects of Melatonin on Fatigue Associated with Breast Cancer and Its Adjuvant Treatments.cited 27× |
| Pediatric-appropriate prolonged-release melatonin (Ped-PRM) | Increases - demonstrate | fatigue | Human | — | — | Assessing the potential for drug interactions and long term safety of melatonin for the treatment of insomnia in children with autism spectrum disorder.cited 6× |